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Abstract
Background and the purpose of the study: Silymarin, a standardized extract of the milk thistle (Silybum
marianum), is believed to exert some of its hepatoprotective effects though inhibition of free radicals and
inflammation. In this study the effect of some pro- and anti-inflammatory cytokines and also antioxidant genes
polymorphisms on the hepatoprotective effects of silymarin in the occupationally exposed individuals to hydrogen
sulfide (H2S) in the sour natural gas refinery was investigated.
Methods: We genotyped seven polymorphisms in six genes reported by others as modifiers of oxidative stress
(NQO1, mEPXH1, GSTT1 and GSTM1) and inflammation (TNF-α and TGF-β1) for an association in effect of
decreasing in liver function tests (LFTs). The LFTs of 77 sour gas refinery workers were measured before and after
administration of silymarin (140 mg, three times per day for 1 month).
Results: A significant reduction of blood AST, ALT and ALP was observed after 30 days of consumption (p < 0.001).
The decreasing effect of silymarin on ALT in the subjects with high producer genotype (A allele carriers) was less
than low producers. There were no significant associations between TGF-β1 and the studied genes of oxidative
stress pathway and the effectiveness of silymarin.
Conclusion: This is the first report about the effectiveness of silymarin in the subjects exposed chronically to H2S.
Meanwhile, the modulatory effect of TNF-α on the effectiveness of silymarin might be used for individualize therapy.
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Introduction
The workers of natural gas refineries are exposed to po-
tentially toxic substances like hydrogen sulfide (H2S) and
benzene. Recently we have shown that the oxidative stress
biomarkers increased in the workers of sweet and, in
higher levels, sour gas refineries [1]. Meanwhile the levels
of liver function tests (LFTs) were high in the H2S exposed
subjects [1]. Although pathogenesis of liver toxicity in-
duced by H2S has not been elucidated so far, there is
experimental evidence that induction of oxidative stress
plays a key role [2,3]. Several observations suggest that
increased reactive oxygen species (ROS) and resulting oxi-
dative stress is a critically important determinant of liver
injury [4,5]. Oxidative stress is involved in the release of
pro-inflammatory mediators (cytokines and chemokines)
and injury to the liver cells [4,5]. Silymarin, a mixture of
flavonolignans isolated from Silybum marianum (milk
thistle), has been used to treat liver diseases for hundreds
of years [6,7]. The hepatoprotective effect of silymarin is
mainly due to its strong antioxidant activity and scaven-
ging the free radicals [8]. It also effectively inhibits the
inflammation [9,10], which can also damage the liver
[6,11]. Silybin is an effective antioxidant, conserving GSH
in liver cells while stabilizing the liver cell membranes
against oxidative attack [4,12].
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There are inter-individual variations in detoxifying
enzymes and cytokines that could be translated into
differences in susceptibility for xenobiotic toxicity and
treatment outcomes [13-17]. So in this study, we decided
to investigate the association of polymorphisms in the en-
zymes involved in general oxidative stress defence including
NAD(P)H:quinone oxidoreductase-1 (NQO1), Glutathione
S-transferases (GST) M1 and T1, and microsomal epoxide
hydrolase (EPHX1) enzymes and the two most important
cytokines involved in the pathogenesis of liver disease with
the basis of inflammation, namely tumor necrosis factor-α
(TNF-α) and transforming growth factor-β1 (TGF-β1)
cytokines and the treatment outcome of silymarin in the
subjects chronically exposed to H2S.
Materials and methods
Materials
Silymarin containing tablets (Livergol) was purchased
from Goldaru, Isfahan, Iran. PCR master mix was obtained
from CinnaClone (Iran). Ethylenediamine tetraacetic acid
(EDTA), Tris, agarose, Sodium Dodecyl Sulfate (SDS),
isopropanol and ethanol were purchased from Merck
(Germany). Proteinase K and DNA ladder were obtained
from Fermentas (Germany).
Study subjects
In this cross-sectional study, 77 employees of sour gas
refinery were recruited. According to local authorities,
the atmospheric concentration of H2S in the place was
10–15 ppm [1]. The eligibility criteria for the cases were
as follow: working at least 5 years in the refinery and no
history of liver disease. Demographic data, general health
conditions, lifestyle, years of employment and smoking
habits were registered in a questionnaire. Written in-
formed consent was obtained from the subjects after
describing the aim of the study. The study was conducted
according to the declaration of Helsinki and subsequent
revisions and approved by the Ethical Committee of
Kerman University of Medical Sciences (No: 91/91/k,
KMU). The liver function tests (LFTs) including aspartate
aminotransferase (AST) and alanine aminotransferase
(ALT) and alkaline phosphatase (ALP) were determined
before and after administration of silymarin at the dosage
of 150 mg three times per day (Livergol, Goldaru, Esfahan,
Iran).
DNA extraction and GST genotyping
DNA was extracted from 5 ml peripheral blood using
Miller method [18]. The subjects were genotyped for the
deletion in GSTM1 and GSTT1 by a multiplex polymerase
chain reaction (PCR). The PCR conditions and primers
were as described previously [19]. TNF-α -308G/A and
TGF-β1 codon 10 and codon 25 genotyping methods were
based on the PCR-ARMS, and were similar to those
previously described [20]. The amplified fragments were
184-bp, 241-bp and 233-bp respectively for TNF-α, TGF-
β1 codon 10 and 25. EPXH1 exon 4 (His139Arg), NQO1
(C609T) and TNF-α (G-308A, for confirmation of PCR-
ARMS for TNF-α -308G/A) genotyping methods were
based on PCR-RFLP and as described before [21-23]. The
products of each PCR reaction and digestion were re-
solved by electrophoresis on 3% agarose gels stained with
ethidium bromide. Reliability and validity of the PCR and
RFLP methods were assessed through re-conducting the
genotype assays using at least a 10% sample of our DNA
samples. The polymorphisms of heterozygous, homozy-
gous and wild-type TNF-α which obtained by PCR-ARMS
were re-checked with PCR-RFLP method. In addition,
for TGF-β1 the method was also assessed through re-
conducting the genotype assays using most of DNA sam-
ples with mutations (both heterozygous and homozygous).
The results for all re-assessments were 100% concordant.
Statistical analysis
For the comparison of continuous variables, we firstly
checked the assumption that they were normally distri-
buted. If the distribution was normal, the results were
expressed as means and standard error (SE) and a classical
t-test or one-way ANOVA was used accordingly. According
to the genes polymorphisms, genotypes were collapsed into
two categories: homozygous (common genotypes) versus
heterozygous + variant homozygous and they were coded
as follow: GSTM1*0 (code 0) and GSTM1-positive (code
1), GSTT1*0 (code 0) and GSTT1-positive (code 1), NQO1
CC allele (code 0) and CT/TT alleles (code 1), EPXH exon
4 AA allele (code 0) and AG/GG alleles (code 1), TGF-β1
codon 10 TT allele (code 0, high producer) and TC/CC
alleles (code 1, low producer), and TGF-β1 codon 25 GG
allele (code 0, high producer) and GC/CC alleles (code 1,
low producer). Combination of TGF-β1 codons 10 and 25
was as follow: TT/GG (code 0, high producer) and all other
combinations (code 1, low producer). Simple and multiple
linear regression was used to screen the independent vari-
ables including genetic polymorphism to best predict the
value of the LFTs and LFTs difference. Age and BMI vari-
ables believed to potentially confound the association with
LFTs’ level were included in the multivariate model. The
significance (P) of genetic polymorphisms factors from
multivariate analysis was considered as adjusted p-value.
Differences between LFTs before and after administration
of silymarin were analyzed using paired-sample t-test. For
all the tests, a p-value less than 0.05 was considered to be
significant. All analyses were conducted using SPSS statis-
tical software (version 11.5).
Results
Significant decreases in AST (P < 0.01), ALT (P < 0.001)
and ALP (P < 0.001) were observed by use of silymarin
Mandegary et al. DARU Journal of Pharmaceutical Sciences 2013, 21:28 Page 2 of 5
http://www.darujps.com/content/21/1/28
(Figure 1). The mean ± SE of AST before and after using
were 39.8 ± 0.78 and 29.7 ± 0.07 U L-1 (Figure 1A). A
significant (P < 0.001) decrease in ALT was observed after
administration of silymarin (66.4 ± 1.4 U L-1 before versus
30.5 ± 0.9 U L-1 after (Figure 1B). After use of silymarin,
the ALP level decreased significantly (P < 0.001). The
mean ± SE values before and after were 231.2 ± 5.9 and
209.2 ± 4.8 U L-1 (Figure 1C).
Simple and multivariate linear regression were performed
to analyze the association of GSTM1, GSTT1, NQO1 and
EPXH1 genes polymorphisms with changes in LFTs after
administration of silymarin (Table 1). There was no associ-
ation between the abovementioned genes’ polymorphisms
and decreasing in LFTs after administration of silymarin.
Simple and multivariate linear regression were performed
to analyze the association of TNF-α, TGF-β1 codon 10,
TGF-β1 codon 25 and combination of these two codons
polymorphisms with changes in LFTs after administration
of silymarin (Table 2). TNF-α G-308A polymorphism was
significantly associated with deceasing in the AST (p = 0.04)
and ALT (p = 0.003). These results show that decreasing in
the AST and ALT levels are lower in the subjects with high
producer TNF-α genotype. These associations remained
significant after adjustment with age and BMI. There was
also negative significant association between TGF-β1
codon 10 polymorphisms and decreasing in ALP that this
association was abolished when age and BMI added to the
model.
Discussion
In light of our recent study demonstrating increase in the
LFT levels in the workers exposed chronically to H2S, we
became interested in determining whether a well-known
hepatoprotective natural product like silymarin could
decrease the LFTs in the subjects and if the genetics of the
subjects could determine responding to treatment. Admin-
istration of silymarin (140 mg tablets, thrice per day for 1 -
month) significantly reduced the LFTs in the subjects. The
hepatoprotective mechanisms of silymarin on H2S-induced
elevation of LFTs have not been addressed so far. Recently
we have also shown that stress oxidative biomarkers were
higher in the workers in exposure to H2S [1]. Lines of evi-
dence demonstrate that stress oxidative is one of the main
mechanisms for the toxic effect of xenobiotics on the liver
[4,15,24]. Antioxidant activity and scavenging the free radi-
cals have been reported as the main mechanism for the
hepatoprotective effect of silymarin [6].
Our data showed significant association (B = −8.30, CI: -
13.73,-2.86) between the polymorphism of TNF-α G-308A
and the changes in ALT and AST after administration of
silymarin (Table 2). In other words, decrease in ALT and
AST in the high TNF-α producers treated with silymarin
is significantly lower than low producers. TNF-α is a pro-
inflammatory cytokine involved in the pathogenesis of
variety of liver injuries [25]. TNF-α, in concert with other
cytokines, mediates the recruitment of neutrophils to the
liver that induce inflammation and cell death [26]. Pro-
duction of TNF-α is under genetic control which deter-
mined by a number of single nucleotide polymorphisms in
this gene. The G-308A polymorphism in the promoter of
the gene is the most studied one that has been linked to


























































Figure 1 Effect of the consumption of silymarin on serum LFTs.
AST (A), ALT (B) and ALP (C) levels in the chronically H2S exposed
subjects (n = 77) were measured before and after administration of
silymarin. Results are expressed as mean ± SE. ** p < 0.001 and *** p
< 0.001 compared with before treatment by Pair sample t-test.
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TNF1 (TNF1/TNF1) is associated with low production
(TNF-αLo), whereas the TNF1/TNF2 and TNF2/TNF2
genotypes are high producers (TNF-αHi). The effect of
TNF-α on the production of ROS was also shown else-
where [25]. TNF-induced ROS production activates JNK
(c-jun N-terminal kinase) by oxidizing and inactivating
several members of the MAP kinase phosphates (MKPs).
Taking together, one might relate the less hepatoprotective ef-
fect of an antioxidant compound like silymarin in high produ-
cer of TNF-α to higher production of ROS in these subjects.
Our data also showed no association between the poly-
morphisms of TGF-β and some of detoxifying enzymes
and the changes in LFTs after administration of silymarin.
Univariate regression analysis showed a significant associ-
ation between TGF-β1 gene polymorphism at codon 10
and ALP levels that this association was abolished after
adjusting the regression with confounders like age and
BMI. This is in consistent with the previous reports about
the role of BMI on the LFTs [29].
Conclusion
Administration of silymarin (140 mg tablets, thrice per day
for 1 month) significantly reduced the LFTs in the subjects
exposed chronically to H2S. Meanwhile, increasing the dose
of silymarin in the high TNF-α producers to obtain thera-
peutic effects might be needed.
Table 1 Association of oxidative stress related genes polymorphisms with changes in LFTs’ levels by consumption of
silymarin
LFT Gene Unadjusted Adjusted
B (CI) p-value B (CI) p-value
AST NQO1 −0.73 (−3.38, 4.84) 0.72 −0.05 (−4.10, 3.92) 0.98
GSTM1 −0.58 (−4. 02, 3.03) 0.75 −0.64 (−4.25, 2.97) 0.72
GSTT1 1.27 (−3.10, 5.64) 0.56 1.92 (−2.55, 6.38) 0.40
EPXH4 1.34 (−3.10, 5.77) 0.54 1.72 (−2.73, 6.17) 0.44
ALT NQO1 0.87 (−4.20, 5.92) 0.73 0.79 (−4.40, 5.98) 0.76
GSTM1 −4.24 (−8. 62, 0.13) 0.05 4.21 (−8.67, 0.25) 0.06
GSTT1 1.30 (−4.23, 6.83) 0.64 1.22 (−4.50, 6.92) 0.65
EPXH4 1.04 (−3.02, 4.67) 0.54 0.89 (−4.46, 6.24) 0.74
ALP NQO1 −12.83 (−39.89, 14.22) 0.35 −2.64 (−20.22, 14.95) 0.76
GSTM1 1.21 (−23.79, 26.21) 0.92 2.27 (−13.67, 18.22) 0.77
GSTT1 21.28 (−8.93, 51.50) 0.16 10.21 (−9.46, 29.87) 0.30
EPXH4 −14.20 (−47.62, 19.22) 0.40 1.73 (−17.78, 21.24) 0.86
Multivariate regression: Parameters adjusted for age and BMI;
B: Partial regression coefficient.
Table 2 Association of inflammation related cytokines polymorphisms with changes in LFTs’ levels by consumption of
silymarin
LFT Gene Unadjusted Adjusted
B (CI) p-value B (CI) p-value
AST TNF-α −4.27 (−8.57, 0.03) 0.05 −4.58 (−8.97, -0.21) 0.04*
TGF-β1 codon 10 −0.77 (−5. 17, 3.61) 0.72 −0.07 (−4.56, 4.41) 0.97
TGF-β1 codon 25 2.78 (−3.36, 8.93) 0.36 2.79 (−3.40, 8.98) 0.37
TGF-β1 codons 10/25 0.99 (−3.04, 5.03) 0.62 1.37 (−2.73, 5.46) 0.50
ALT TNF-α −8.30 (−13.73, -2.86) 0.003* −8.93 (−14.62, -3.23) 0.003*
TGF-β1 codon 10 −3.62 (−8.92, 1.67) 0.17 −3.43 (−9.00, 2.14) 0.22
TGF-β1 codon 25 5.87 (−1.29, 13.03) 0.10 5.94 (−1.36, 13.24) 0.10
TGF-β1 codons 10/25 −0.33 (−5.28, 4.63) 0.89 0.03 (−5.11, 5.24) 0.99
ALP TNF-α −6.17 (−41.08, 28.75) 0.72 −0.85 (−21.93, 20.21) 0.93
TGF-β1 codon 10 −31.45 (−61.31, -1.59) 0.03 −9.05 (−27.43, 8.32) 0.33
TGF-β1 codon 25 16.67 (−25.38, 58.73) 0.43 −12.00 (−37.17, 13.17) 0.34
TGF-β1 codons 10/25 −16.16 (−44.41, 12.07) 0.25 −8.65 (−24.63, 7.33) 0.28
Multivariate regression: Parameters adjusted for age and BMI. *Significant effect. B: Partial regression coefficient.
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